TrialNature medicine2023

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.

Jesper D Gunst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.